AUTISM

NTI’s two clinical trial results are in - Treatment success for BOTH Autism AND for Rett Syndrome

Next Investors Apr 17, 2024

Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.

NTI Begins Autism Clinical Trials for Unique Cannabis Strain

Catalyst Hunter Archived May 05, 2021

Neurotech International Ltd (ASX: NTI) has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD) for its unique cannabis strain.

NTI secures strategic Cultivation partnership to grow and maintain its medical cannabis

Finfeed Archived Mar 09, 2021

Neurotech International Limited (ASX: NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.

Neurotech to commence clinical study program this quarter

Finfeed Archived Feb 15, 2021

Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.

NTI Days Away from Crucial Lab Results – Can its Cannabis Strain Treat Autism?

Catalyst Hunter Archived Dec 16, 2020

Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.

Neurotech’s trial-backed device a new frontier for kids with autism

Finfeed Archived Aug 16, 2018

Neurotech International (ASX:NTI) has developed a neurofeedback device that helps children with autistic spectrum disorders (ASD) to focus and positively engage with the world around them.